CNS Pharmaceuticals, Inc. Financing Cash Flow
CNS Pharmaceuticals, Inc. (CNSP) reported Financing Cash Flow of $20.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $20.58M, a 364.93% increase year-over-year.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $404.66K, a 95.88% decline year-over-year.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $406.87K, a 91.80% decline year-over-year.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$91.95K, a 100.75% decline year-over-year.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $14.57M, a 36.74% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $23.03M, a 396.63% increase from fiscal 2023.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $4.64M, a 70.30% decline from fiscal 2022.
- CNS Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $15.61M, a 246.26% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $20.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $20.98M 10-Q · filed 2026-08-12 | $21.39M derived: sum of 3 quarters · filed 2026-08-12 | $21.30M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $404.66K 10-Q · filed 2026-05-14 | $811.53K derived: sum of 2 quarters · filed 2026-05-14 | $719.58K derived: sum of 3 quarters · filed 2026-05-14 | $5.15M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $406.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $314.92K derived: sum of 2 quarters · filed 2026-03-31 | $4.74M derived: sum of 3 quarters · filed 2026-08-12 | $14.57M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$91.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.33M derived: sum of 2 quarters · filed 2026-08-12 | $14.16M 10-Q · filed 2025-11-14 | $19.13M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $4.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $14.25M 10-Q · filed 2026-08-12 | $14.25M 10-Q · filed 2025-08-14 | $19.22M derived: sum of 3 quarters · filed 2026-08-12 | $31.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.83M 10-Q · filed 2026-05-14 | $14.79M derived: sum of 2 quarters · filed 2026-05-14 | $27.07M derived: sum of 3 quarters · filed 2026-05-14 | $29.40M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $17.24M derived: sum of 2 quarters · filed 2026-03-31 | $19.57M derived: sum of 3 quarters · filed 2026-03-31 | $23.03M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $12.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $14.61M derived: sum of 2 quarters · filed 2025-11-14 | $18.07M 10-Q · filed 2025-11-14 | $20.24M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.79M 10-Q · filed 2025-08-14 | $7.96M derived: sum of 3 quarters · filed 2025-08-14 | $7.97M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $3.46M 10-Q · filed 2025-05-15 | $5.64M derived: sum of 2 quarters · filed 2025-05-15 | $5.64M derived: sum of 3 quarters · filed 2025-05-15 | $8.22M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.19M derived: sum of 2 quarters · filed 2025-03-31 | $4.76M derived: sum of 3 quarters · filed 2025-03-31 | $4.64M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $8.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.58M derived: sum of 2 quarters · filed 2024-11-14 | $2.46M 10-Q · filed 2024-11-14 | $7.79M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.45M 10-Q · filed 2024-08-14 | $7.78M derived: sum of 3 quarters · filed 2024-08-14 | $7.67M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$120.28K 10-Q · filed 2024-05-15 | $5.21M derived: sum of 2 quarters · filed 2024-05-15 | $5.10M derived: sum of 3 quarters · filed 2024-05-15 | $4.98M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.22M derived: sum of 2 quarters · filed 2024-04-01 | $5.10M derived: sum of 3 quarters · filed 2024-04-01 | $15.61M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$117.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$233.31K derived: sum of 2 quarters · filed 2023-11-14 | $10.28M 10-Q · filed 2023-11-14 | $10.20M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$116.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $10.40M 10-Q · filed 2023-08-14 | $10.31M derived: sum of 3 quarters · filed 2023-08-14 | $13.75M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $10.51M 10-Q · filed 2023-05-15 | $10.43M derived: sum of 2 quarters · filed 2023-05-15 | $13.87M derived: sum of 3 quarters · filed 2023-05-15 | $14.67M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$82.83K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.35M derived: sum of 2 quarters · filed 2023-03-31 | $4.16M derived: sum of 3 quarters · filed 2023-03-31 | $4.51M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.24M derived: sum of 2 quarters · filed 2022-11-10 | $4.59M 10-Q · filed 2022-11-10 | $18.77M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $808.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.16M 10-Q · filed 2022-08-12 | $15.33M derived: sum of 3 quarters · filed 2022-08-12 | $15.29M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $347.43K 10-Q · filed 2022-05-13 | $14.53M derived: sum of 2 quarters · filed 2022-05-13 | $14.48M derived: sum of 3 quarters · filed 2022-05-13 | $14.48M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $14.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $14.13M derived: sum of 2 quarters · filed 2022-03-03 | $14.13M derived: sum of 3 quarters · filed 2022-03-03 | $14.13M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$45.00K derived: sum of 2 quarters · filed 2021-11-12 | -$45.00K 10-Q · filed 2021-11-12 | $8.78M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $8.83M derived: sum of 3 quarters · filed 2021-08-13 | $8.93M derived: sum of 4 quarters · filed 2021-08-13 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | $8.83M derived: sum of 2 quarters · filed 2021-05-13 | $8.93M derived: sum of 3 quarters · filed 2021-05-13 | $10.31M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $8.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $8.93M derived: sum of 2 quarters · filed 2021-02-12 | $10.31M derived: sum of 3 quarters · filed 2021-02-12 | $10.26M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $96.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.48M derived: sum of 2 quarters · filed 2020-11-12 | $1.43M 10-Q · filed 2020-11-12 | $1.44M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.33M 10-Q · filed 2020-08-10 | $1.34M derived: sum of 3 quarters · filed 2020-08-10 | ||
| 2019-03-31 | -$48.02K 10-Q · filed 2020-05-15 | -$42.02K derived: sum of 2 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.16M 10-K · filed 2020-03-12 | |||
| 2018-09-30 | $1.15M 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |